antifungal resistance – Page 5

Drug repurposing to fight resistant fungal species: Recent developments as novel therapeutic strategies

mycolabadmin

Fungal infections are becoming increasingly difficult to treat due to growing drug resistance, affecting millions of people worldwide each year. This research collection explores creative solutions by repurposing existing medications and developing new combination therapies that work better together against resistant fungal species. Studies show promising results combining common antibiotics like minocycline with antifungal drugs, and natural compounds from traditional medicine show potential for treating hard-to-treat infections like Candida and Aspergillus.

Endogenous Endophthalmitis: An underestimated serious complication in patients with disseminated fusariosis

mycolabadmin

An 18-year-old leukemia patient developed a serious fungal eye infection from Fusarium during cancer treatment. The infection spread through the bloodstream to both eyes, causing serious inflammation and vision loss. Doctors treated it with multiple antifungal medications injected directly into the eyes along with systemic medication, which controlled the infection but unfortunately the patient’s vision was significantly affected. This case highlights how rare but serious eye infections can occur in cancer patients with weakened immune systems.

Continuous debridement combined with short-term posaconazole therapy for cutaneous mucormycosis caused by Rhizopus oryzae infection secondary to acute myeloid leukemia: a case report

mycolabadmin

An 80-year-old patient with acute myeloid leukemia developed a serious fungal skin infection caused by Rhizopus oryzae on his lower leg. Doctors treated the infection by repeatedly cleaning out the infected tissue and giving him an antifungal medication called posaconazole for just one week. Despite the short treatment duration due to cost concerns, the patient’s wound gradually healed over four months through continued surgical care, showing that sometimes focused surgical treatment can be as effective as long-term medication.

Candida blankii: The Difficult Capture of a Fungus With Pathogenic Potential

mycolabadmin

Candida blankii is a rare fungal pathogen that is increasingly being found in hospital patients’ bloodstreams and respiratory tracts. The organism is difficult to identify using standard laboratory tests, which can delay diagnosis and treatment. This case report describes two adult patients with C. blankii infections and highlights the challenges in identifying this emerging pathogen and its resistance to common antifungal medications.

A prospective, multicenter study of invasive fungal disease caused by molds in children and adults in Chile

mycolabadmin

Researchers studied serious fungal infections caused by molds in Chilean hospitals and found that aspergillus was the most common culprit, affecting both children and adults. Many patients with these infections were also suffering from COVID-19, showing how serious respiratory viruses can increase the risk of fungal complications. Good news: the study found no resistance to common antifungal medications in Chile yet, though overall survival rates remain concerning at around 60% at three months.

Traumatic implantation keratitis caused by Schizophyllum commune in Central India

mycolabadmin

This report describes two patients in India who developed serious fungal eye infections (keratitis) after corneal injuries. The infection was caused by Schizophyllum commune, a mushroom-like fungus found on decaying wood. Despite aggressive treatment with antifungal medications and surgery, both patients lost vision in their affected eyes. The case highlights how difficult it is to identify and treat this rare fungus.

Metabolic Patterns of Fluconazole Resistant and Susceptible Candida auris Clade V and I

mycolabadmin

Researchers used advanced chemical analysis to identify different compounds produced by a dangerous fungus called Candida auris that can cause serious infections. They compared fungal strains that were resistant to the antifungal drug fluconazole with those that were susceptible, finding that resistant strains produced different metabolites (chemical compounds) than susceptible ones. These findings could help doctors develop better treatments by identifying what makes this fungus resistant to current medications.

Aspergillus fumigatus dsRNA virus promotes fungal fitness and pathogenicity in the mammalian host

mycolabadmin

A virus that infects the fungus Aspergillus fumigatus makes the fungus more dangerous by helping it survive stress and resist immune cell attack. When researchers removed the virus from the fungus, it became weaker and less harmful to infected mice. Treating infected mice with an antiviral drug called ribavirin reduced the virus, lowering fungal burden and improving survival, suggesting that targeting fungal viruses could be a new way to treat serious fungal infections.

Spread of Antifungal-Resistant Trichophyton indotineae, United Kingdom, 2017–2024

mycolabadmin

A fungal infection called Trichophyton indotineae, which originated in Asia, is rapidly spreading throughout the United Kingdom and becoming resistant to common antifungal treatments. The infection typically starts in the groin area and can spread to other parts of the body, and many cases fail to respond to standard antifungal drugs like terbinafine. Researchers tracked 157 cases over seven years and found the fungus now accounts for over a third of all dermatophyte infections sent to the UK reference laboratory. Doctors and laboratory professionals are being urged to recognize this emerging threat and consider better diagnostic and treatment strategies.

Prospective Study on Microbiological Profile of Fungal Isolates and its Antibiogram in a Tertiary care hospital in South India

mycolabadmin

Researchers studied fungal infections in a hospital in South India over one year, examining 62 fungal isolates. They found that Candida auris, a dangerous fungal species, was the most common and had developed resistance to many antifungal drugs. A newer class of antifungal drugs called echinocandins worked best against these infections, highlighting the importance of quick identification of fungal species for proper treatment.

Research Keyword: antifungal resistance